PE20060997A1 - PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVES - Google Patents
PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVESInfo
- Publication number
- PE20060997A1 PE20060997A1 PE2006000132A PE2006000132A PE20060997A1 PE 20060997 A1 PE20060997 A1 PE 20060997A1 PE 2006000132 A PE2006000132 A PE 2006000132A PE 2006000132 A PE2006000132 A PE 2006000132A PE 20060997 A1 PE20060997 A1 PE 20060997A1
- Authority
- PE
- Peru
- Prior art keywords
- equal
- less
- benzisoxazole
- side effects
- reduce
- Prior art date
Links
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA DOSIS D DE UN DERIVADO DE BENZISOXAZOL TAL COMO RISPERIDONA, PALIPERIDONA Y METABOLITOS ACTIVOS PARA USO FARMACEUTICO. DICHA COMPOSICION, DE LIBERACION PROLONGADA, PROPORCIONA: A) UNA CONCENTRACION MAXIMA DE PLASMA, DE LA MEDIA, DE DOSIS SIMPLE DEL DERIVADO DE BENZISOXAZOL Y METABOLITOS ACTIVOS CARACTERIZADA POR LA RELACION 0,5 ng/ml/mg MENOR O IGUAL Cmax/D MENOR O IGUAL 8 ng/ml/mg; B)UN AREA DE DOSIS SIMPLE, DE LA MEDIA DE UNA CURVA DE TIEMPO DE CONCENTRACION DE PLASMA PARA AUCinf DEL DERIVADO DE BENZISOXAZOL Y METABOLITOS ACTIVOS CARACTERIZADA POR 30 ng hr/ml/mg MENOR O IGUAL AUCinf/D MENOR O IGUAL 300 ng hr/ml/mg. LA COMPOSICION FARMACEUTICA, DE ACUERDO A LAS CARACTERISTICAS MENCIONADAS, REDUCEN O ELIMINAN CIERTOS EFECTOS SECUNDARIOS DE RISPERIDONA Y SU METABOLITO PALIPERIDONA, EN EL TRATAMIENTO DE TRASTORNOS PSICOTICOSREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING A DOSE DOSE OF A BENZISOXAZOLE DERIVATIVE SUCH AS RISPERIDONE, PALIPERIDONE AND ACTIVE METABOLITES FOR PHARMACEUTICAL USE. SUCH COMPOSITION, OF PROLONGED RELEASE, PROVIDES: A) A MAXIMUM CONCENTRATION OF PLASMA, OF THE AVERAGE, SINGLE DOSE OF THE DERIVATIVE OF BENZISOXAZOLE AND ACTIVE METABOLITES CHARACTERIZED BY THE RATIO 0.5 ng / ml / mg LESS OR EQUAL Cmax / D LESS OR EQUAL 8 ng / ml / mg; B) A SIMPLE DOSE AREA OF A MEAN OF A PLASMA CONCENTRATION TIME CURVE FOR AUCinf OF THE DERIVATIVE OF BENZISOXAZOLE AND ACTIVE METABOLITES CHARACTERIZED BY 30 ng hr / ml / mg LESS OR EQUAL AUCinf / D LESS OR EQUAL 300 ng hr / ml / mg. THE PHARMACEUTICAL COMPOSITION, ACCORDING TO THE MENTIONED CHARACTERISTICS, REDUCE OR ELIMINATE CERTAIN SIDE EFFECTS OF RISPERIDONE AND ITS METABOLITE PALIPERIDONE, IN THE TREATMENT OF PSYCHOTIC DISORDERS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/051,060 US20050208132A1 (en) | 2002-07-29 | 2005-02-04 | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060997A1 true PE20060997A1 (en) | 2006-10-11 |
Family
ID=38048170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000132A PE20060997A1 (en) | 2005-02-04 | 2006-02-02 | PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVES |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR053671A1 (en) |
PE (1) | PE20060997A1 (en) |
TW (1) | TW200638936A (en) |
UY (1) | UY29363A1 (en) |
-
2006
- 2006-02-02 PE PE2006000132A patent/PE20060997A1/en not_active Application Discontinuation
- 2006-02-03 AR ARP060100402 patent/AR053671A1/en unknown
- 2006-02-03 TW TW095103673A patent/TW200638936A/en unknown
- 2006-02-06 UY UY29363A patent/UY29363A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR053671A1 (en) | 2007-05-16 |
TW200638936A (en) | 2006-11-16 |
UY29363A1 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190390A1 (en) | CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE INHIBITOR | |
CL2017003445A1 (en) | Solid forms and formulations of imidazopyrazine compounds. | |
NI201000003A (en) | TRISUSTITUED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES. | |
AR108594A2 (en) | PHARMACEUTICAL FORMULATIONS THAT KEEP FLAVOR WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS | |
AR061771A1 (en) | THERAPEUTIC ADMINISTRATION SYSTEM | |
UY29701A1 (en) | LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES | |
ECSP088974A (en) | IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3) | |
AR084691A1 (en) | TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER | |
PE20180203A1 (en) | PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINE-2- [1- (2-FLUOROBENZYL) -1H-PIRAZOLO [3,4-B] PYRIDIN-3-IL] PYRIMIDIN-5-IL} METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE | |
ECSP088973A (en) | IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3) | |
AR061166A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE | |
PE20211818A1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING A DERIVATIVE OF AMINOPYRIMIDINE OR ITS SALT | |
CL2021003034A1 (en) | Methods of treatment of sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
CO2022017622A2 (en) | nek7 kinase inhibitors | |
CL2010000524A1 (en) | Use of a topical composition comprising 3.75% imiquimod and a pharmaceutically acceptable carrier to prepare a medicament useful for treating genital or perianal warts. | |
AR047469A1 (en) | ANTIMICROBIAL PRESERVANTS TO ACHIEVE A MULTIPLE DOSE FORMULATION USING BETA CYCLODEXTRINES FOR LIQUID DOSAGE FORMS | |
AR064543A1 (en) | USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS | |
CO2022019131A2 (en) | nek7 kinase inhibitors | |
MX2023003758A (en) | Pharmaceutical formulations. | |
CR10210A (en) | BENZOISOINDOL DERIVATIVES FOR PAIN TREATMENT | |
ES2616882T3 (en) | Pharmaceutical composition comprising an adenosine A3 receptor agonist (IB-MECA / CF-101) for the treatment of psoriasis | |
UY29561A1 (en) | DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
AR075866A1 (en) | A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION | |
AR059225A1 (en) | CITRATE SALT, PREPARATION PROCESS AND ITS ACTIVITY IN THERAPY | |
ES2526359T3 (en) | Oral galenic formulation comprising ketorolac and B vitamins, in which vitamin B6 is in an external layer separated from the rest of active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |